Testing effectiveness (Phase 2)Study completedNCT06097663
What this trial is testing
Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Who this might be right for
Coronary Heart DiseaseClonal Hematopoiesis of Indeterminate Potential (CHIP)
Novartis Pharmaceuticals 31